Sinovant and Roivant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia
- Cytovant licenses East Asian rights for a research-stage T-cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene?s dendritic cell (DC) vaccine for the treatment of patients across East Asia
- Cytovant and Medigene to collaborate on research and discovery of two additional TCRs tailored for patients in East Asia
- Medigene receives an upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestones and low double-digit royalties
- John Xu, PhD, former President and Chief Scientific Officer of Mab-Legend Biotech, named President of Cytovant